Lilly’s mirikizumab beats placebo in pivotal ulcerative colitis trial

Eli Lilly and Company (NYSE:LLY) announced that its interleukin-23 subunit p19 inhibitor mirikizumab achieved its primary endpoint of clinical remission at 52 weeks in the Phase 3 LUCENT-2 study.

Lilly says mirikizumab is the first anti-IL23p19 to demonstrate maintenance of clinical remission in a Phase 3 ulcerative colitis study.

Janssen (NYSE:JNJ) has ongoing clinical trials testing its interleukin-23 subunit p19 inhibitor guselkumab (Tremfya) as an inflammatory bowel disease therapy. Studies are ongoing testing guselkumab for adults with moderately to severely active ulcerative colitis.

Participants in Lilly’s LUCENT-2 study were previously enrolled in a 12-week induction study known as LUCENT-1.

Subjects in LUCENT-2 were rerandomized to receive mirikizumab maintenance dosing.

Lilly notes that a statistically higher number of mirikizumab recipients achieved clinical remission at one year than placebo recipients.

“Bowel urgen…

Read more
  • 0